Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
about
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaGenetic manipulation for inherited neurodegenerative diseases: myth or reality?Nanoparticle-based targeted therapeutics in head-and-neck cancerLentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindnessGene therapy for hemophiliaPerformance-enhancing substances in sports: a review of the literatureDiverse activities of viral cis-acting RNA regulatory elements revealed using multicolor, long-term, single-cell imagingCell loss during pseudoislet formation hampers profound improvements in islet lentiviral transduction efficacy for transplantation purposes.Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrantsAAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis modelChimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.Immunization delivered by lentiviral vectors for cancer and infectious diseases.In vitro evaluation of a double-stranded self-complementary adeno-associated virus type2 vector in bone marrow stromal cells for bone healing.Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo."Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.Integration site choice of a feline immunodeficiency virus vector.Increase in the titer of lentiviral vectors expressing potassium channels by current blockade during viral vector productionAdvances in Gene Delivery Systems.Genetic control of wayward pluripotent stem cells and their progeny after transplantation.Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.Fully-spliced HIV-1 RNAs are reverse transcribed with similar efficiencies as the genomic RNA in virions and cells, but more efficiently in AZT-treated cells.Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms.Cardiovascular gene delivery: The good road is awaitingPredicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.Control of viral infectivity by tripartite motif proteins.Development of lentiviral vectors with regulated respiratory epithelial expression in vivoGene therapy for treatment of inherited haematological disorders.Sleeping Beauty transposon system--future trend in T-cell-based gene therapies?New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesIntrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral VectorsHematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityLentivirus vector can be readministered to nasal epithelia without blocking immune responsesViral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Lentivirus as a potent and mechanistically distinct vector for genetic immunizationTherapeutic siRNA for drug-resistant HER2-positive breast cancer.
P2860
Q24632975-C02BFB22-1B74-4E50-AC8E-156B67757C57Q26752831-7AF66CDB-CB91-4D9A-A448-7607C0FA7E0FQ26999699-668A7671-BEE2-4AF1-93E9-576400E59ADDQ27307727-F5BA77D1-71F1-4E19-91CB-75C7ED821E68Q28081911-5F8A82F6-17E2-40EB-97B5-E81A3C1C4383Q28256659-E2E79E96-26A7-4127-B6BA-30D7457AD4DAQ30841153-0D967229-4E27-4405-A9BE-941015C932B2Q33294626-86AE2CB2-E840-49CB-A91B-8B6990FDC7A0Q33412009-96E68994-874C-4168-944D-986D884198FFQ34214323-2F362ABF-483B-418F-BBA6-2F3CCB757B16Q34256494-E536D573-0F4B-4D22-BB9B-0F3CF7F229B4Q34539879-CDA9F3A3-FA3A-4791-8FC9-44F94FA374BFQ34668056-7DCD0C0E-069B-41A4-9A3A-8D8A5721AA72Q34727843-ECA0DCDA-377B-4076-96AC-9EF6C5AB9112Q34994534-4E9D9311-8929-484A-8415-CFC59607C829Q35024080-9BB23A0E-7B6B-40DB-ACE4-D982DF23720AQ35622018-905295B3-BA2E-41C7-AB40-F379A645808AQ35632772-5EC8414B-DEF7-46E5-9D82-F1634E7DF135Q35661899-66669304-275F-4DFE-96A7-C9DD4C55A5C8Q35688089-15EDAA5C-041F-40DA-B517-6D45F30784F9Q35791255-3CEF46CF-6DC7-498F-B23F-9A55FEB297A1Q35823611-10170F35-27BD-48AE-8CF0-B5BA307DC5F7Q35829334-B41D693B-18BB-4194-BA8C-83EF3C4B93C8Q35915765-48247B06-55BF-44DA-A1E1-F7BB960805CAQ36187534-F3F06DEB-A75E-4C89-BB8D-FDEB18CFE47BQ36201277-943A8689-1042-45CC-BC6F-477D7D1B6C3AQ36283603-79008FE3-7EB6-42E3-A165-61E83F22686BQ36330666-3947D5A6-AD33-44A3-AA04-C9035F63C5F9Q36446948-F5E4E717-7264-4F42-A2CD-985DE326A73AQ36512502-5CAC15E6-1A26-4D10-AABE-91507602DF7EQ36558375-D9A90583-08DB-4678-8C59-3841D2A5181BQ36587580-71551321-6BBA-468F-8ECC-0F49CFF210E1Q36673678-9A9245CA-805A-43A7-9127-599C54866B89Q36784555-FB7BDAF5-DC82-453D-8D06-040F218A8428Q36842738-F8337894-769A-4544-963B-D34638170E99Q36915859-95BADA03-60A3-41ED-A3CD-948E1455E703Q36949698-78914B6C-06C1-4621-8718-64B850DABBE8Q36960666-1BDEA765-753D-43E3-B8E0-45E54B43A96BQ36969195-935F1723-46C6-42ED-9C59-01520CA2FE42Q37046699-D6676985-AC4F-46FE-9BC7-04B5CD9B8E37
P2860
Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Gene therapy progress and pros ...... gn, biosafety, and production.
@ast
Gene therapy progress and pros ...... gn, biosafety, and production.
@en
type
label
Gene therapy progress and pros ...... gn, biosafety, and production.
@ast
Gene therapy progress and pros ...... gn, biosafety, and production.
@en
prefLabel
Gene therapy progress and pros ...... gn, biosafety, and production.
@ast
Gene therapy progress and pros ...... gn, biosafety, and production.
@en
P2860
P356
P1433
P1476
Gene therapy progress and pros ...... ign, biosafety, and production
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302570
P577
2005-07-01T00:00:00Z